Physician profile
Rohit Rai
NPI 1538319710
$7,200.61
in general payments reported to CMS, 2019-2025
36 companies · $1,087 in 2025
The $1,087 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $947 · 2020: $1,012 · 2021: $1,149 · 2022: $1,190 · 2023: $938 · 2024: $876 · 2025: $1,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,901.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,901.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $893.65 | 2019-2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $575.73 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $569.55 | 2019-2023 | Jardiance |
| Mannkind Corporation | $517.25 | 2022-2025 | Afrezza |
| Novo Nordisk INC | $458.61 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $452.05 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $435.95 | 2019-2025 | Breztri, Farxiga, Airsupra |
| E.R. Squibb & Sons, L.L.C. | $359.79 | 2019-2025 | Eliquis |
| Abbvie INC. | $325.09 | 2021-2025 | |
| Intuity Medical INC | $313.79 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Lilly USA, LLC | $280.27 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $208.39 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $200.82 | 2019-2022 | |
| Exact Sciences Corporation | $174.00 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $166.17 | 2019-2025 | Xifaxan, Trulance |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $161.55 | 2020 | |
| Amgen INC. | $149.38 | 2022-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $110.36 | 2023-2024 | Rexulti |
| Corcept Therapeutics | $96.41 | 2024 | Korlym |
| Abbott Laboratories | $82.61 | 2021-2022 | |
| Genzyme Corporation | $80.65 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.99 | 2025 | |
| Novartis Pharmaceuticals Corporation | $68.62 | 2020-2022 | |
| Esperion Therapeutics, INC. | $60.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $56.19 | 2024-2025 | Dupixent |
| Boston Scientific Corporation | $50.44 | 2022-2023 | Watchman Flx |
| Paratek Pharmaceuticals, INC. | $43.92 | 2022 | |
| Dexcom, INC. | $42.15 | 2022 | |
| Xeris Pharmaceuticals, INC. | $39.69 | 2025 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $36.68 | 2023 | Livalo, Seglentis |
| Medtronic, INC. | $22.72 | 2021 | |
| Amarin Pharma, INC. | $22.12 | 2020 | |
| Vivus LLC | $18.31 | 2019 | |
| Avanir Pharmaceuticals, INC. | $17.95 | 2020 | |
| Melinta Therapeutics, LLC | $16.90 | 2019 | |
| Genentech USA, INC. | $15.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Rai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.